ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Association of Cumulative Exposure to Triglyceride and Remnant Cholesterol With the Risk of Cardiovascular Disease in Hypertensive Patients With Target LDL-C.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk in Populations With Different Low-Density Lipoprotein Cholesterol Elevations: A Prospective Cohort Study.Journal of the American Heart Association · 2026Article
- Associations of insulin resistance-related indices with incident carotid plaques by cardiovascular risk profiles: a prospective cohort study.Lipids in health and disease · 2026Article
- Prognostic value of combined LDL-C and remnant cholesterol stratification for 24-month major adverse cardiovascular events after primary PCI in patients with STEMI.Frontiers in cardiovascular medicine · 2026Article
- Critical Appraisal of Remnant Cholesterol as a Predictor of Cardiovascular Risk in Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive patients are at high risk of cardiovascular disease (CVD) and require intensive lipids management. Triglycerides (TG) and remnant cholesterol (RC) contribute to residual risk beyond low-density lipoprotein cholesterol (LDL-C), and cumulative exposure reflects a more comprehensive assessment. However, their impact on hypertensive patients with target LDL-C levels remains unclear. A total of 9046 hypertensive participants with target LDL-C levels who completed three health examinations (2006‒2010) were enrolled and followed until December 31, 2022. Cumulative burden was calculated as the average level multiplied by the interval between assessments. The primary outcome included a composite of CVD events (myocardial infarction [MI], ischemic stroke [IS], and hemorrhage stroke [HS]). Participants were categorized into four groups according to cumulative triglyceride (cumTG) (≥5.66 vs. <5.66 [median, mmol/L]) and cumulative RC (cumRC) (≥4.20 vs. <4.20 [median, mmol/L]): low cumTG and low cumRC, high cumTG and low cumRC, low cumTG and high cumRC, and high cumTG and high cumRC. Cox models were used to calculate the hazard ratio (HR) and 95% confidence intervals (CI) between the cumulative burden and CVD risk. During a median follow-up of 15.97 years, 1415 participants developed CVD. After multivariable adjustment, compared to the low cumTG/low cumRC group, CVD risk was higher in the high cumTG/high cumRC (HR 1.43, 95% CI 1.24‒1.64) and low cumTG/high cumRC groups (HR 1.24, 95% CI 1.05-1.47), but not in the high cumTG/low cumRC group (HR 1.06, 95% CI 0.89-1.25). In hypertensive patients with target LDL-C levels, high cumRC, rather than cumTG, is associated with an increased risk of CVD. Trial Registration: ChiCTR-TNC-11001489.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.